

Accepted Manuscript

Title: Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients



Authors: Rafael Reis, Laurence Labat, Marie Allard, Pascaline Boudou-Rouquette, Jeanne Chapron, Audrey Bellesoeur, Audrey Thomas-Schoemann, Jennifer Arrondeau, Frédérique Giraud, Jérôme Alexandre, Michel Vidal, François Goldwasser, Benoît Blanchet

PII: S0731-7085(17)32902-3
DOI: <https://doi.org/10.1016/j.jpba.2018.05.052>
Reference: PBA 12003

To appear in: *Journal of Pharmaceutical and Biomedical Analysis*

Received date: 23-11-2017
Revised date: 28-5-2018
Accepted date: 30-5-2018

Please cite this article as: Rafael Reis, Laurence Labat, Marie Allard, Pascaline Boudou-Rouquette, Jeanne Chapron, Audrey Bellesoeur, Audrey Thomas-Schoemann, Jennifer Arrondeau, Frédérique Giraud, Jérôme Alexandre, Michel Vidal, François Goldwasser, Benoît Blanchet, Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients, *Journal of Pharmaceutical and Biomedical Analysis* <https://doi.org/10.1016/j.jpba.2018.05.052>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients.

Rafael Reis^{a*}, Laurence Labat^{a,b}, Marie Allard^a, Pascaline Boudou-Rouquette^c, Jeanne Chapron^d, Audrey Bellesoeur^e, Audrey Thomas-Schoemann^{e,f}, Jennifer Arrondeau^c, Frédérique Giraud^d, Jérôme Alexandre^c, Michel Vidal^{a,f}, François Goldwasser^c, Benoît Blanchet^{a,f}

^aPharmacokinetics and Pharmacochemistry Unit, CERIA, Cochin Hospital, APHP, Paris Descartes, CARPEM, 75014 Paris, France

^bInserm UMR - S1144, University of Paris Descartes – Paris Diderot, France

^cOncology Unit, CERIA, Cochin Hospital, APHP, University of Paris Descartes, CARPEM, 75014 Paris, France

^dPneumology Unit, Cochin Hospital, APHP, 75014 Paris, France

^eMultidisciplinary Risk Assessment and Drug Monitoring Unit, CERIA, Cochin Hospital, APHP, 75014 Paris, France

^fUMR8638 CNRS, Pharmacy UFR, University of Paris Descartes, PRES sorbonne Paris Cité, France

***Corresponding Author:** R. Reis, PharmD,

Pharmacokinetics and Pharmacochemistry Unit, Cochin Hospital, 27 rue du Faubourg Saint Jacques, 75014 Paris, France, Tel: + 33 1 58 41 23 13, Fax: + 33 1 58 41 23 15
Email: rafael.reis@aphp.fr

Download English Version:

<https://daneshyari.com/en/article/7626199>

Download Persian Version:

<https://daneshyari.com/article/7626199>

[Daneshyari.com](https://daneshyari.com)